title: Biologicals in Juvenile Idiopathic Arthritis.
abstract: We share our experience with biological agents in children with juvenile idiopathic arthritis with an aim to highlight the adverse events and response to treatment. Out of a total of 10 children treated with biological agents, one patient had serious infection, all showed good response and none had tuberculosis. High cost was limiting factor for their use.
authors.affiliation: Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India skkabra@hotmail.com.
authors.forename: Isha
authors.initials: I
authors.lastname: Saini
authors.forename: Lesa
authors.initials: L
authors.lastname: Dawman
authors.forename: Neerja
authors.initials: N
authors.lastname: Gupta
authors.forename: S K
authors.initials: SK
authors.lastname: Kabra
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D000068800:Etanercept / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000069594:Abatacept; C502936:tocilizumab; D000068800:Etanercept